文献速递围术期管理与 ERAS甲状腺与颈部外科

经皮穴位电刺激对比甲氧氯普胺治疗中重度术后恶心呕吐的随机临床试验

Transcutaneous Electrical Acupoint Stimulation vs Metoclopramide for Moderate to Severe Postoperative Nausea and Vomiting: A Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2026-01-01

该随机双盲对照试验在4家医院纳入232例25-55岁女性甲状腺或颈前手术后中重度PONV患者,比较 wearable TEAS(PC6穴位)与静脉甲氧氯普胺10mg的疗效。TEAS组2小时缓解率显著更高(77.6% vs 55.2%,P<.001),24小时复发率更低(12.2% vs 56.3%,P<.001),无不良事件报告。

要点

  • wearable TEAS装置刺激PC6穴位2小时,对中重度PONV的2小时缓解率优于甲氧氯普胺10mg。
  • TEAS组24小时复发率显著低于甲氧氯普胺组,且未报告不良事件。
  • TEAS可作为药物控制不佳的中重度PONV的非药物替代选择。

核心结论

  • 可穿戴TEAS在治疗中重度PONV方面显著优于甲氧氯普胺,是一种有效的非药物替代方案,有助于促进麻醉后恢复。

研究设计与样本

  • 随机、双模拟、患者和观察者盲法、平行组、阳性对照临床试验,在中国上海和天津4家医院进行,2024年5月至2025年5月。
  • 纳入25-55岁女性,计划在全身麻醉下接受甲状腺切除术或颈前手术,并出现中重度PONV(NRS≥4)。
  • 共筛查310例,232例(74.8%)随机分为TEAS组(n=116)或对照组(n=116),全部完成试验,采用符合方案分析。
  • 干预:TEAS组使用EmeTerm腕带主动刺激2小时并注射生理盐水安慰剂;对照组使用相同外观的非主动TEAS装置并静脉注射甲氧氯普胺10mg。
  • 2小时未缓解(NRS≥4)者再次随机交叉干预。

主要发现

  • TEAS组2小时PONV缓解率(NRS≤3)为77.6%(95%CI 69.2%-84.2%),对照组为55.2%(95%CI 46.1%-63.9%),P<.001。
  • TEAS组24小时复发率为12.2%(95%CI 7.0%-20.6%),对照组为56.3%(95%CI 44.1%-67.7%),P<.001。
  • 未报告不良事件。
  • 232例患者平均(SD)年龄43.5(5.1)岁,100%为女性。

临床怎么用

  • 对于甲状腺或颈前手术后出现中重度PONV的女性患者,可考虑使用可穿戴TEAS装置刺激PC6穴位作为甲氧氯普胺的替代或辅助治疗。
  • TEAS治疗2小时后评估疗效,若NRS≥4可考虑交叉干预或改用其他止吐方案。

局限性

  • 研究仅纳入25-55岁女性甲状腺或颈前手术患者,结果外推至其他人群和手术类型需谨慎。
  • 采用符合方案分析,未报告意向性分析结果。
  • 随访时间较短,仅报告24小时复发率,缺乏更长期结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Moderate to severe postoperative nausea and vomiting (PONV) significantly impedes recovery and is inadequately managed by current pharmacotherapy. OBJECTIVE: To evaluate the clinical efficacy of a novel wearable transcutaneous electrical acupoint stimulation (TEAS) device targeting the PC6 (Neiguan) acupoint in managing moderate to severe PONV. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-dummy, patient-blinded and observer-blinded, parallel-group, and active-controlled clinical trial was conducted at 4 hospitals in Shanghai and Tianjin, China, from May 2024 through May 2025. Eligible participants were female patients aged 25 to 55 years scheduled for thyroidectomy or anterior cervical surgery undergoing general anesthesia who developed moderate to severe PONV (numerical rating score [NRS] ≥4). These data were analyzed during June 2025. INTERVENTIONS: Participants were randomized 1:1 to receive either active TEAS via the EmeTerm wristband applied for 2 hours with a saline placebo injection or an identical inactive TEAS device (model stimulator) with intravenous metoclopramide, 10 mg. Participants not achieving symptom relief (NRS ≥4) at 2 hours underwent rerandomization to cross-intervention. MAIN OUTCOME AND MEASURE: The primary outcome was the 2-hour PONV remission rate following initial intervention defined as a significant relief in symptoms (NRS ≤3). RESULTS: A total of 310 patients were screened for eligibility and 232 (74.8%) were randomized into either TEAS group (n = 116) or control group (n = 116). All participants completed the trial and a per-protocol analysis was conducted. Among 232 total patients, mean (SD) age was 43.5 (5.1) years and 100% were female. The TEAS group demonstrated a significantly higher 2-hour remission rate (77.6%; 95% CI, 69.2%-84.2% vs 55.2%; 95% CI, 46.1%-63.9%; P < .001) and a lower 24-hour relapse rate (12.2%; 95% CI, 7.0%-20.6% vs 56.3%; 95% CI, 44.1%-67.7%; P < .001) compared with controls. No adverse events were reported. CONCLUSION AND RELEVANCE: In this study, wearable TEAS significantly outperformed metoclopramide for moderate to severe PONV, representing an effective nonpharmacological alternative that enhances postanesthesia recovery. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR2400084329.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Zheng DY, Ding P, Gong M, et al. Transcutaneous Electrical Acupoint Stimulation vs Metoclopramide for Moderate to Severe Postoperative Nausea and Vomiting: A Randomized Clinical Trial. JAMA Surg. 2026. PMID: 41604189. doi:10.1001/jamasurg.2025.6394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。